Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications
By Ying Wang, Xiaodong Chen, W. Cao, Yufang Shi. Nature Immunology, 2014
1,264 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology, Rehabilitation
View Paper: https://www.semanticscholar.org/paper/911fdfa670169a0d2ffd66628f2f1f931b2e3f42
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Mesenchymal stem cells and immunomodulation: current status and future prospects (2016, background): “NO is another soluble factor known to inhibit T-cell proliferation.(42,43) It has been”
- New horizons in tumor microenvironment biology: challenges and opportunities (2015, result): “In contrast to TAMs, which compose a terminal lineage, MSCs remain primitive and can generate adipocytes, pericytes, chondrocytes, neurons, osteocytes, and mainstay stromal cells, including fibroblasts and endothelial cells, and can also transdifferentiate into both ectodermal and endodermal cells, ”
- COVID-19: Transmission, prevention, and potential therapeutic opportunities (2020, positive): “In order to improve the effectiveness of MSC-induced anti-inflammatory response, they could be pretreated using IFN-γ, which is low or absent in severe COVID-19 [133].”
- Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs (2019, background): “Whilst MSCs can exhibit immunosuppressive or immuneenhancing properties depending on the presence or absence of certain inflammatory or anti-inflammatory stimuli, the tumorigenic potential of living MSCs poses a risk that cannot be neglected (26, 28, 106).”
- Mesenchymal stromal cells: clinical challenges and therapeutic opportunities (2018, background): “of adjacent and distant responder cells and tissue(Wang et al., 2014).”
- COVID-19 infection: the perspectives on immune responses (2020, background): “Such cytokine-licensed MSCs could be more effective in the suppression of hyperactive immune response and promotion of tissue repair, as licensed-MSCs are effective in LPSinduced acute lung damage [6] .”